Syncom Formulations (India) Ltd

Stage 2 · Advancing · week 8

As of 16 Oct 2026, Syncom Formulations (India) is in Stage 2 — advancing, the uptrend phase, in week 8 (since 26 Aug 2026). It closed at ₹21.95, 16.2% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. More about the company

₹22
+1.81% today
₹2,063 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #57 of 59 in Pharmaceuticals · #68 of 70 in Health Care

Is SYNCOMF early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-16.2%
₹10.3 lo₹26.2 hi
16.2% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
46.7%
200 DMA: ₹15 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.38x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
MA20 trending up · +7.7% vs MA50 +22.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+19.2%
3M
+63.0%
6M
+57.3%
YTD
+48.5%
1Y
+28.4%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #29 of 66 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #25 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 28w
S3 17w
S2 18w
S3 14w
S4 36w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 7w → S2 28w → S3 17w → S2 18w → S3 14w → S4 11w → S1 6w → S2 5w → S3 2w → S4 36w → S1 12w → S4 3w → S3 1w → S2 7w current
Total tracked: 168 weeks across 14 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-26
3 appearances in last 60 days. First seen: 2024-07-22.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 8 · Vol 0.38x
2026-10-15S2
Wk 7 · Vol 0.38x
2026-10-14S2
Wk 7 · Vol 0.50x
2026-10-13S2
Wk 7 · Vol 0.70x
2026-10-12S2
Wk 7 · Vol 0.80x
2026-10-09S2
Wk 7 · Vol 0.75x
2026-10-08S2
Wk 6 · Vol 0.72x
2026-10-07S2
Wk 6 · Vol 2.15x
2026-10-06S2
Wk 6 · Vol 0.82x
2026-10-05S2
Wk 6 · Vol 1.12x
2026-10-01S2
Wk 6 · Vol 2.56x
2026-09-30S2
Wk 5 · Vol 6.48x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹19.5
200 DMA
₹15
52W High
₹26.2
52W Low
₹10.3
5D Low
₹21.6
Resistance levels (recent highs)
20d High
₹26.2
60d High
₹26.2
120d High
₹26.2
250d High
₹26.2
Next resistance
+19.3%
to 20d High
Ask the Market AI about SYNCOMFAsk →
P/E (TTM)
21.4
Forward —
Earnings Growth (YoY)
+68.8%
Revenue +0.7%
ROE
+20.2%
Profit margin +14.7%
About this companyHealth Care· Pharmaceuticals

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.